Mianserine Biogaran (Mianserin Hydrochloride)

• Mianserin is used primarily within the antidepressant therapeutic class to treat depressive disorders.
• Major depressive disorder: reduces depressive symptoms and improves mood in adult patients.
• Depressive episodes in adults: alleviates core symptoms during acute phases.
• Treatment‑resistant depression: may be considered as an alternative when first‑line agents are ineffective.

• Mianserin acts as an antagonist of central presynaptic α2‑adrenergic receptors, increasing norepinephrine release. It also blocks histamine H1 receptors and serotonin 5‑HT2 and 5‑HT3 receptors, thereby enhancing noradrenergic and serotonergic neurotransmission in the brain, which contributes to its antidepressant effect.

Mianserine Biogaran may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Drowsiness
• Dry mouth
• Weight gain
• Constipation
• Dizziness

Serious or Rare Side Effects

• Agranulocytosis
• Seizures
• Severe hypotension
• Cardiac arrhythmias
• Hepatic dysfunction

When prescribing Mianserine Biogaran, clinicians should observe several precautionary measures to ensure patient safety.

• Monitor blood pressure: watch for orthostatic hypotension, especially during initiation.
• Assess for suicidal ideation: evaluate mental status regularly in the early treatment phase.
• Evaluate hepatic function: consider liver enzyme testing before and during therapy.
• Use caution in elderly patients: increased risk of sedation and falls.
• Avoid abrupt discontinuation: taper dose under medical supervision to reduce withdrawal symptoms.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mianserine Biogaran can interact with several medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• MAO inhibitors: concurrent use may cause hypertensive crisis or serotonin syndrome.
• SSRIs or other serotonergic agents: combined therapy increases risk of serotonin syndrome.
• CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs: may enhance hypotensive effects, requiring blood pressure monitoring.
• Carbamazepine: enzyme induction can reduce Mianserin plasma levels, potentially diminishing efficacy.